Most patients with type 2 diabetes are inadequately controlled on their current therapy. Suboptimal glycemic control can have devastating consequences, such as retinopathy, nephropathy, neuropathy, and cardiovascular disease that may ultimately lead to mortality. Most patients eventually need insulin therapy, and initiating insulin earlier in the course of type 2 diabetes may lead to optimal glycemic control and prevent or delay diabetes-related complications. Although insulin therapy is the most effective method of managing hyperglycemia, it is often delayed owing to concerns about the complexity and inconvenience of treatment regimens; fear of injections, hypoglycemia or weight gain; and the time required to learn how to effectively manage insulin therapy. The development of insulin analogs, biphasic insulin analogs, and more convenient insulin delivery systems may make insulin therapy more manageable and help more patients achieve their treatment goals.
* Current approaches to managing type 2 diabetes that delay the use of insulin often fail to provide effective glycemic control.
* Initiating insulin earlier in the course of treatment may improve glycemic control, which may prevent or delay the development of diabetes-related complications.
* The greater safety and convenience of insulin analogs compared to regular human insulin therapies may help reduce resistance to initiating insulin among patients and practitioners and facilitate the earlier use of insulin therapy.